F L Ampil1, G V Burton, B D Li, G M Mills. 1. Division of Radiation Oncology, Louisiana State University School of Medicine, Shreveport 71130, USA.
Abstract
PURPOSE: To evaluate the effects in women of the timing of breast irradiation (BI) in relation to the application or non-application of adjuvant chemotherapy after breast conservation surgery (BCS) for early stage cancer. METHODS: Between October 1981 and June 1995, 47 women with stage I and II breast cancer underwent BCS. Twenty-six patients did not receive adjuvant chemotherapy (NAC) and 21 women did (AC). In the NAC group, BI commenced within (n = 9) or after (n = 17) seven weeks following BCS; in the AC group, 18 women received BI more than 24 weeks after BCS and three patients within 24 weeks. RESULTS: In the NAC group, there was a trend toward more local and systemic failures plus a definite correlation with poorer survival (p = 0.05) when BI was initiated more than 7 weeks after BCS. In the AC group, the locoregional and systemic failures occurred only in women with a delay of BI exceeding 24 weeks; survival was not different between the subgroups. CONCLUSION: An undue delay of BI should be avoided in patients after BCS whether they require adjuvant chemotherapy for early stage breast cancer or not.
PURPOSE: To evaluate the effects in women of the timing of breast irradiation (BI) in relation to the application or non-application of adjuvant chemotherapy after breast conservation surgery (BCS) for early stage cancer. METHODS: Between October 1981 and June 1995, 47 women with stage I and II breast cancer underwent BCS. Twenty-six patients did not receive adjuvant chemotherapy (NAC) and 21 women did (AC). In the NAC group, BI commenced within (n = 9) or after (n = 17) seven weeks following BCS; in the AC group, 18 women received BI more than 24 weeks after BCS and three patients within 24 weeks. RESULTS: In the NAC group, there was a trend toward more local and systemic failures plus a definite correlation with poorer survival (p = 0.05) when BI was initiated more than 7 weeks after BCS. In the AC group, the locoregional and systemic failures occurred only in women with a delay of BI exceeding 24 weeks; survival was not different between the subgroups. CONCLUSION: An undue delay of BI should be avoided in patients after BCS whether they require adjuvant chemotherapy for early stage breast cancer or not.
Authors: Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Walter J Curran; Luis Souhami; Jeff M Michalski; C Leland Rogers; Benjamin W Corn Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: J Stefoski Mikeljevic; R Haward; C Johnston; A Crellin; D Dodwell; A Jones; P Pisani; D Forman Journal: Br J Cancer Date: 2004-04-05 Impact factor: 7.640
Authors: Raffaella Caponio; Maria Paola Ciliberti; Giusi Graziano; Rocco Necchia; Giovanni Scognamillo; Antonio Pascali; Sabino Bonaduce; Anna Milella; Gabriele Matichecchia; Cristian Cristofaro; Davide Di Fatta; Pasquale Tamborra; Marco Lioce Journal: Eur J Med Res Date: 2016-08-11 Impact factor: 2.175